The HLA typing market is projected to reach USD 2.1 billion in 2028 from USD 1.4 billion in 2022 with a CAGR of 6.5% during the forecast period. Growth in the HLA typing market is mainly driven by factors such as the rising number of organ transplantation procedures, rising technological advancements in HLA typing, increasing funding investments for research activities, and the growing prevalence of infectious diseases worldwide.
The HLA typing market is semi-consolidated/competitive. The key market players’ key strategies include product launches and approvals, agreements, and acquisitions. As of 2021, the Prominent players in the global HLA typing market include Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), and bioMérieux S.A. (France). Other players in the market are Immucor, Inc. (US), Illumina, Inc. (US), Luminex Corporation (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), GenDx (Netherlands), and Biofortuna (UK), among others.
To know about the assumptions considered for the study download the pdf brochure
Market players are moving toward offering more comprehensive solutions to end-user organizations through strategic agreements and acquisitions. The HLA typing market is well-established in North America and most developed countries in Europe. The focus of market players on emerging markets in the Asia Pacific and Latin America is increasing.
Bio-Rad Laboratories is engaged in developing, manufacturing, and marketing products used to identify, separate, analyze, and purify complex chemical and biological materials. The company operates through two business segments, namely, Life Science and Clinical Diagnostics. Through its Clinical diagnostic, the company offers instruments and reagents for HLA typing.
Bio-Rad Laboratories holds a significant position in the global transplant diagnostics market. The company focuses on further strengthening its position in this industry by adopting product commercialization as its key growth strategy. Bio-Rad Laboratories also focuses on strengthening its R&D capabilities to assist in the pipeline development of innovative transplant diagnostic products in order to expand its consumer base and offer its existing customers novel products.
Bio-Rad Laboratories operates in more than 150 countries, with manufacturing facilities located in the US, France, Switzerland, Germany, and Singapore. The company operates its global business through more than 40 subsidiaries, including Bio-Rad Laboratories Pty. Limited (Australia), Bio-Rad Laboratorios Brasil Ltda. (Brazil), Bio-Rad Laboratories Shanghai Limited (China), Bio-Rad Laboratories G.m.b.H. (Germany), Bio-Rad Laboratories Limited (Canada), Bio-Rad Korea Limited (South Korea), Bio-Rad Fujirebio Inc. (Japan), and Bio-Rad spol. sr. o. (Czech Republic).
F. Hoffmann-La Roche
F. Hoffmann-La Roche Ltd. (Roche) is a pharmaceutical and diagnostics company based in Switzerland. The company is engaged in the development, manufacture, distribution, and marketing of therapeutic and diagnostic products. Roche operates through two business divisions, namely, Pharmaceuticals and Diagnostics. The Diagnostics division is further segmented into Core Lab, Pathology & Point of Care Solutions, Molecular Diagnostics, and Diabetes Care. The company offers its HLA products through its Molecular Diagnostics business segment.
Roche products have achieved consistent quality because of automation, which also allows the business to scale up and down in response to market demand.
Excellent Results in New Markets - Roche has developed expertise in entering new markets and succeeding in them. The company's expansion has helped it develop new revenue streams and diversify the risk of the economic cycle in the markets it serves.
The business made significant financial investments in the online platform over the last few years. For Roche, this investment has created new sales channels. The business can take advantage of this opportunity in the coming years by getting to know its customers better and meeting their needs with the help of big data analytics. For instance- The digital PCR system.
The growth of the market will erode competitors' competitive advantages and boost Roche's ability to compete with its rivals.
Roche operates in more than 100 countries, including the US, Australia, China, Denmark, Germany, India, Italy, Japan, Malaysia, Poland, Singapore, and the UK. The company has 26 manufacturing sites, including 17 pharmaceutical manufacturing sites, 7 diagnostic manufacturing sites, and 2 joint manufacturing sites. The company also has 30 R&D facilities across the globe for pharmaceutical & diagnostics. Roche distributes and sells its products across 180 countries and has over 50 subsidiaries. Its major subsidiaries include Roche Diagnostics Ltd. (UK), Roche Diagnostics Corporation (US), Hoffman La Roche Ltd. (Canada), Roche Holding Ltd. (Switzerland), Roche Diagnostics Australia Pty Ltd., Roche Diagnostics Oy (Finland), Roche Diagnostics (India) Pvt. Ltd., and Roche Diagnostics France SAS.
QIAGEN is engaged in the development, manufacture, distribution, and marketing of analytical products that are used for pre-analytical sampling and molecular assays. The company’s consumer base includes molecular diagnostic laboratories, applied testing laboratories, and pharmaceutical companies. The company operates through two business divisions, namely, Instrumentation and Consumables & Related Revenues. The company offers infectious disease testing, HLA typing, and next-generation sequencing products used for donor-recipient screening through the Consumables & Related Revenues segment.
QIAGEN has a major market presence in the US, Canada, Brazil, Mexico, Germany, the UK, Switzerland, France, Japan, Australia, Canada, and Italy. Its major subsidiaries include QIAGEN Inc. (US), QIAGEN Ltd. (UK), QIAGEN Pty. Ltd. (Australia), QIAGEN Benelux B.V. (Belgium), QIAGEN Inc. (Canada), QIAGEN Nordic (Denmark), QIAGEN GmbH (Germany), QIAGEN K.K. (Japan), Amnisure International, LLC (US), Intelligent Bio-Systems, Inc. (Australia), QIAGEN Australia Holding Pty. Ltd., QIAGEN Hamburg GmbH (Germany), and QIAGEN Manchester Ltd. (UK).
Thermo Fisher Scientific
Thermo Fisher Scientific is a leading life science research and diagnostics manufacturing company engaged in the development, manufacture, commercialization, and distribution of analytical instruments, equipment, reagents & consumables, software, and services. The company operates through four business segments, namely, Analytical Instruments, Laboratory Products & Biopharma Services, Life Sciences Solutions, and Specialty Diagnostics. The Life Sciences Solutions segment provides PCR- and NGS-based reagents, instruments, and software used during HLA typing procedures. The company offers HLA products through “ONE LAMBDA” a thermofisher scientific brand.
Thermo Fisher Scientific is one of the leading product manufacturers for life science research and medical diagnostic products. The company focuses on launching technologically advanced products in order to maintain its leadership position in the transplant diagnostics industry. The company focuses on strengthening its revenue growth and brand positioning in the transplant diagnostics industry by adopting growth strategies, such as acquisitions and expansions. Thermo Fisher Scientific has acquired several companies, such as Patheon (Netherlands), Finesse Solutions (US), and Affymetrix (US). These acquisitions enabled the company to expand and strengthen its genomic analysis product portfolio as well as develop innovative diagnostic technologies.
Thermo Fisher Scientific operates across 60 countries and has a strong presence in North America, Europe, the Asia Pacific, Africa, and the Middle East. The company operates its global operations through ~800 subsidiaries, including Fisher Scientific Company (US), Fisher Scientific Jersey Island (UK), Laboratory Management Systems Inc. (US), One Lambda, Inc. (US), and Life Technologies Corporation (US).
HLA Typing Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) & Region - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE